Retatrutide: how it works and what the data show

What is Retatrutide?

Retatrutide (LY-3437943) is an experimental peptide agonist that triply activates the GLP-1, GIP and glucagon receptors. Retatrutide is studied in metabolic research models, including obesity and type 2 diabetes.

Its structure is designed to contain a lipophilic side chain, which prolongs the half-life and allows once-weekly administration in the studies.

Mechanism of action – what it does in the body

• GLP-1 receptor (GLP-1R): enhances glucose-dependent insulin secretion, delays gastric emptying and suppresses appetite.

• GIP receptor (GIPR): Retatrutide is ~8.9 times more potent than natural GIP — improving the post-meal insulin response.

• GCGR (glucagon receptor): although with lower activity (≈30–40%), activation of GCGR improves liver metabolism, mobilisation of liver lipids and energy expenditure.

• Multiple signalling effect: the combination promotes weight loss through reduced appetite + higher metabolism, as well as improved glycaemic and lipid markers.

Clinical data – what the stages of the trial showed

48-week study (Phase 2, MASLD)

• High doses (8 and 12 mg) led to a mean weight loss of 22.8% and 24.2% from baseline.

• Liver fat (LF): at 12 mg — reduction of up to –82.4% after 24 weeks and –86.0% after 48 weeks.

24-week study in obesity

• Mean weight loss: 17.5% at the 12 mg dose.
  
  
  

Patients with type 2 diabetes

• Study in The Lancet: Retatrutide significantly improved glycaemic control and was associated with a significant reduction in body weight, with an adverse-event profile similar to other GLP-1 agonists such as semaglutide and tirzepatide.

How does Retatrutide compare with Semaglutide and Tirzepatide?

• Tri-receptor synergy: combines appetite suppression, insulin support and lipid mobilisation — a stronger metabolic action than the dual agonists.

• Weight loss in studies: up to 24% at 48 weeks (phase 2, versus placebo) – in separate studies ~15% with semaglutide and ~22% with tirzepatide, not in a head-to-head comparison

• Additional data: regulation of liver fat, triglycerides and apoC-III (up to –40.6% and –38% respectively) — as recorded in clinical studies.
  
  

Structural and pharmacological optimisations

• It contains a lipophilic condensed segment, ensuring high durability and weekly administration.

• It is being studied in phase III programmes for diabetes, MASLD and obesity.

Brief summary: mechanism → effect

Target/receptor	Effect of retatrutide	Clinical outcome
GLP-1R	↑ insulin, ↓ appetite, ↓ gastric emptying	Better glucose, satiety
GIPR	Strong insulinogenic response	Post-meal control
GCGR	Energy mobilisation, lipid mobilisation	Increased metabolism
All + accumulation	Synergistic metabolic effect	Weight loss up to –24.2

Conclusion

Retatrutide is a triple GLP-1/GIP/GCGR agonist — in phase 2 studies the combination of appetite suppression, increased metabolism and glycaemic regulation was associated with a mean reduction in body weight of up to 24.2%, as well as an improvement in liver fat and metabolic markers. The phase 3 programme is continuing.